Poseida Therapeutics (STU:2RZ) Growth Rank : 0 (As of Jun. 23, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics Growth Rank?

Poseida Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Poseida Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Poseida Therapeutics (STU:2RZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (STU:2RZ) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

PSTX:USA

Address

9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.poseida.com

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Poseida Therapeutics (STU:2RZ) Headlines

No Headlines